- لا يوجد منتجات
* ViCTOZA (Liraglutide) 6 mg/ml Solution for injection in pre-filled pen 2 x 3 ml. [glucagon-like peptide-1 (GLP-1) Receptor Agonist, used as adjunctive therapy in type 2 diabetes mellitus].
* Subcutaneous (S.C.) use. {Victoza must not be administered intravenously or intramuscularly}.
* Therapeutic indications:
Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
* Pharmacotherapeutic group:
Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins. ATC code: A10BX07
* Mechanism of action:
Liraglutide is a GLP-1 analogue with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Unlike native GLP-1, liraglutide has a pharmacokinetic and pharmacodynamic profile in humans suitable for once daily administration. Following subcutaneous administration, the protracted action profile is based on three mechanisms: self-association, which results in slow absorption; binding to albumin; and higher enzymatic stability towards the dipeptidyl peptidase -4 (DPP-4) and neutral endopeptidase (NEP) enzymes, resulting in a long plasma half-life.
Liraglutide action is mediated via a specific interaction with GLP-1 receptors, leading to an increase in cyclic adenosine monophosphate (cAMP). Liraglutide stimulates insulin secretion in a glucose-dependent manner. Simultaneously, liraglutide lowers inappropriately high glucagon secretion, also in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. Conversely, during hypoglycaemia liraglutide diminishes insulin secretion and does not impair glucagon secretion. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying. Liraglutide reduces body weight and body fat mass through mechanisms involving reduced hunger and lowered energy intake.
* 2 pens:
Each pen contains 3 ml solution, delivering 30 doses of 0.6 mg, 15 doses of 1.2 mg or 10 doses of 1.8 mg.
* 1 ml contains 6 mg of liraglutide.
One pre-filled pen contains 18 mg liraglutide.
Disodium phosphate dihydrate, propylene glycol, phenol and water for injections.
* Do not store the pen with a needle attached.
* Store in a refrigerator (2-8 degrees C). Do not freeze.
* After use of the pen, store below 30 degrees C or in a refrigerator (2-8 degrees C). Do not freeze. Keep the pen cap on in order to protect from light.
* Discard the pen 1 month after first use.
* Victoza pen is designed to be used with NovoFine and NovoTwist disposable needle. Needles are not included.
المراجعات
لا توجد مراجعات بعد.